Hippotherapy as a Complementary Intervention for Multiple Sclerosis: A Review
DOI:
https://doi.org/10.12775/QS.2025.48.66934Keywords
hippotherapy, equine-assisted therapy, multiple sclerosisAbstract
Introduction: Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS). The pathogenesis of multiple sclerosis is complex and incompletely understood. The major factors that lead to the disease seem to be inflammation and neurodegeneration. Multiple sclerosis is diagnosed by meeting diagnostic criteria. They are based on demonstrating the involvement of 2 or more areas of the CNS at different time points. There remains no cure for multiple sclerosis. Treatment has three aspects: symptom management, relapse management, and disease-modifying therapy. Despite the benefits of pharmacological and non-pharmacological treatments, studies indicate that several complementary therapies may also be promising. One such therapy is hippotherapy, an equine-assisted form of physical therapy that uses the characteristic movements of a horse.
Aim of the study: The aim of this study was to review the published literature on the impact of hippotherapy on multiple sclerosis.
Materials and methods: A review of available studies examining the relationship between hippotherapy and multiple sclerosis was conducted. To identify relevant literature, the PubMed and Google Scholar databases were used.
Results: Several studies investigating the effect of hippotherapy as a complementary intervention on the course of multiple sclerosis indicate that this intervention can be beneficial for affected patients. Patients in the hippotherapy intervention group showed improvements in balance, fatigue, spasticity, walking performance, spatiotemporal gait parameters, processing of sensory cues for postural control, trunk and upper-limb control, dynamic control, facilitated movement, and quality of life.
Conclusions: Hippotherapy may be a useful complementary treatment for improving walking and other functional outcomes in people with multiple sclerosis, but the available evidence remains limited and further studies are needed.
References
1. Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018 Dec;31(6):752-759. doi: 10.1097/WCO.0000000000000622. PMID: 30300239.
2. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018 Apr 21;391(10130):1622-1636. doi: 10.1016/S0140-6736(18)30481-1. Epub 2018 Mar 23. PMID: 29576504.
3. Katz Sand I. Classification, diagnosis, and differential diagnosis of multiple sclerosis. Curr Opin Neurol. 2015 Jun;28(3):193-205. doi: 10.1097/WCO.0000000000000206. PMID: 25887774.
4. Kuceyeski AF, Vargas W, Dayan M, et al. Modeling the relationship among gray matter atrophy, abnormalities in connecting white matter, and cognitive performance in early multiple sclerosis. AJNR Am J Neuroradiol. 2015;36:702-709.
5. Rojas JI, Patrucco L, Miguez J, et al. Brain atrophy in radiologically isolated syndromes. J Neuroimaging. 2015;25:68-71.
6. Biberacher V, Boucard CC, Schmidt P, et al. Atrophy and structural variability of the upper cervical cord in early multiple sclerosis. Mult Scler. 2014; doi: 10.1177/1352458514546514.
7. Nygaard GO, Walhovd KB, Sowa P, et al. Cortical thickness and surface area relate to specific symptoms in early relapsing-remitting multiple sclerosis. Mult Scler. 2015;21:402-414.
8.Perez-Miralles F, Sastre-Garriga J, Tintore M, et al. Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler. 2013;19:1878-1886.
9.Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun. 2014 Feb-Mar;48-49:134-142. doi: 10.1016/j.jaut.2014.01.022. Epub 2014 Feb 10. PMID: 24524923.
10. Costello FE, Burton JM. Multiple sclerosis: eyes on the future. J Neuroophthalmol. 2018 Mar;38(1):81-84. doi: 10.1097/WNO.0000000000000631. PMID: 29438264.
11. Vidal-Jordana A, Montalban X. Multiple sclerosis: epidemiologic, clinical, and therapeutic aspects. Neuroimaging Clin N Am. 2017 May;27(2):195-204. doi: 10.1016/j.nic.2016.12.001. PMID: 28391781.
12. Montague T, Drummond J, Ng K, Parratt J. Advancements in multiple sclerosis. Intern Med J. 2025 Jun;55(6):895-904. doi: 10.1111/imj.70023. Epub 2025 Apr 2. PMID: 40171883; PMCID: PMC12155068.
13. Marcus R. What is multiple sclerosis? JAMA. 2022;328(20):2078. doi: 10.1001/jama.2022.14236.
14. Vermöhlen V, Schiller P, Schickendantz S, Drache M, Hussack S, Gerber-Grote A, Pöhlau D. Hippotherapy for patients with multiple sclerosis: a multicenter randomized controlled trial (MS-HIPPO). Mult Scler. 2018 Sep;24(10):1375-1382. doi: 10.1177/1352458517721354. Epub 2017 Aug 3. PMID: 28770664.
15. D’Isanto T. Sport adapted hippotherapy for disabled people affected by multiple sclerosis. J Phys Educ Sport. 2023;23(5):1150-1155.
16. Koca TT, Ataseven H. What is hippotherapy? The indications and effectiveness of hippotherapy. North Clin Istanb. 2016 Jan 15;2(3):247-252. doi: 10.14744/nci.2016.71601. PMID: 28058377; PMCID: PMC5175116.
17. du Plessis N, Uys K, Buys T. Hippotherapy concepts: a scoping review to inform transdisciplinary practice guidelines. Scand J Occup Ther. 2023;30(8):1424-1440. doi: 10.1080/11038128.2023.2231562.
18. Moraes AG, Neri SGR, Motl RW, Tauil CB, Glehn FV, Corrêa ÉC, de David AC. Effect of hippotherapy on walking performance and gait parameters in people with multiple sclerosis. Mult Scler Relat Disord. 2020 Aug;43:102203. doi: 10.1016/j.msard.2020.102203. Epub 2020 May 26. PMID: 32485633.
19. Muñoz-Lasa S, López de Silanes C, Atín-Arratibel MÁ, Bravo-Llatas C, Pastor-Jimeno S, Máximo-Bocanegra N. Effects of hippotherapy in multiple sclerosis: pilot study on quality of life, spasticity, gait, pelvic floor, depression and fatigue. Med Clin (Barc). 2019 Jan 18;152(2):55-58. doi: 10.1016/j.medcli.2018.02.015. Epub 2018 Apr 19. PMID: 29680460.
20. Silkwood-Sherer D, Warmbier H. Effects of hippotherapy on postural stability in persons with multiple sclerosis: a pilot study. J Neurol Phys Ther. 2007 Jun;31(2):77-84. doi: 10.1097/NPT.0b013e31806769f7. PMID: 17558361.
21. Lindroth JL, Sullivan JL, Silkwood-Sherer D. Does hippotherapy affect use of sensory information for balance in people with multiple sclerosis? Physiother Theory Pract. 2015;31(8):575-581. doi: 10.3109/09593985.2015.1067266. Epub 2015 Oct 14. PMID: 26467902.
22. Gencheva N. Evaluation of hippotherapy in the course of multiple sclerosis treatment. Act Phys Educ Sport. 2015;5(2):183-187.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Sylwia Bryksy, Agnieszka Przybyłowska , Natalia Popczyk, Jakub Jopek, Agnieszka Piechowicz , Michał Popczyk, Aleksandra Marciszewska, Martyna Świątecka, Jakub Kaźmierczyk

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 22
Number of citations: 0